Psychedelic drugs have resurged in neuroscience and psychiatry with promising success in psychedelic-assisted therapy for the treatment of anxiety, depression, and addiction. At the cellular level, psychedelic drugs elicit neuroplastic processes 24 h after administration, priming neural circuits for change. The acute effects of psychedelic drugs are well characterized with functional imaging and neural oscillations showing an increase in the entropy of spontaneous cortical activity.
Hypotheses:
We hypothesized that cortical–striatal oscillations recorded in rats would confirm the effects of psychedelic drugs. We also hypothesized that brain stimulation delivered 24 h after lysergic acid diethylamide (LSD) administration would lead to different effects than brain stimulation alone.
Methods:
We recorded local field potential oscillations from rats after LSD or saline (SAL) administration and determined whether exposure to these treatments altered the effect of a targeted intervention (brain stimulation) 24 h later.
Results:
We confirmed acutely decreased low frequency power across the brain when rats are given LSD. We also demonstrated these altered states return to baseline after 24 h. Brain stimulation applied in the previously reported window of heightened neuroplasticity produced distinct shifts in brain state compared with brain stimulation applied 24 h after SAL administration.
Conclusions:
Despite the acute effects of LSD disappearing after 24 h, there are still latent effects that interact with brain stimulation to create larger and distinct changes in brain activity compared with brain stimulation alone. Our proof-of-concept findings are the first to suggest that psychedelic drugs could work in combination with brain stimulation to achieve enhanced effects on brain activity and future study will assess impacts on stimulation-induced changes in behavior.
Get full access to this article
View all access options for this article.
References
1.
GriffithsRR, JohnsonMW, CarducciMA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol, 2016; 30(12):1181–1197.
2.
MitchellJM, BogenschutzM, LiliensteinA, et al. MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat Med, 2021; 27(6):1025–1033.
3.
YadenDB, GriffithsRR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci, 2021; 4(2):568–572.
4.
HesselgraveN, TroppoliTA, WulffAB, et al. Harnessing psilocybin: Antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci U S A, 2021; 118(17):e2022489118; doi: 10.1073/pnas.2022489118
5.
SmigielskiL, ScheideggerM, KometerM, et al. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Neuroimage, 2019; 196:207–215.
6.
MuthukumaraswamySD, Carhart-HarrisRL, MoranRJ, et al. Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci, 2013; 33(38):15171–15183.
7.
MurrayCH, TareI, PerryCM, et al. Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. Psychopharmacology (Berl), 2022; 239(6):1735–1747; doi: 10.1007/s00213-021-05991-9
8.
LyC, GrebAC, VargasMV, et al. Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth. ACS Pharmacol Transl Sci, 2021; 4(2):452–460.
9.
FlanaganTW, BillacGB, LandryAN, et al. Structure-activity relationship analysis of psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore. ACS Pharmacol Transl Sci, 2021; 4(2):488–502.
10.
HouseRV, ThomasPT, BhargavaHN. Immunological consequences of in vitro exposure to lysergic acid diethylamide (LSD). Immunopharmacol Immunotoxicol, 1994; 16(1):23–40.
11.
SzaboA.Psychedelics and immunomodulation: Novel approaches and therapeutic opportunities. Front Immunol, 2015; 6:358.
12.
ShaoL-X, LiaoC, GreggI, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron, 2021; 109(16):1253–2544.e4; doi: 10.1016/j.neuron.2021.06.008
13.
Moda-SavaRN, MurdockMH, ParekhPK, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science, 2019; 364(6436):eaat8078; doi: 10.1126/science.aat8078
14.
OrnelasIM, CiniFA, WießnerI, et al.Nootropic effects of LSD: Behavioral, molecular and computational evidence. Exp Neurol, 2022; 356:114148.
15.
FrankelPS, CunninghamKA. The hallucinogen d-lysergic acid diethylamide (d-LSD) induces the immediate-early gene c-Fos in rat forebrain. Brain Res, 2002; 958(2):251–260.
NolteG, BaiO, WheatonL, et al. Identifying true brain interaction from EEG data using the imaginary part of coherency. Clin Neurophysiol, 2004; 115(10):2292–2307.
18.
DoucetteWT, DwielL, BoyceJE, et al.Machine learning based classification of deep brain stimulation outcomes in a rat model of binge eating using ventral striatal oscillations. Front Psychiatry, 2018; 9:336.
19.
PhipsonB, SmythGK.Permutation P-values should never be zero: Calculating exact P-values when permutations are randomly drawn. Stat Appl Genet Mol Biol, 2010; 9:Article39.
20.
GodaSA, PiaseckaJ, OlszewskiM, et al. Serotonergic hallucinogens differentially modify gamma and high frequency oscillations in the rat nucleus accumbens. Psychopharmacology, 2013; 228(2):271–282.
21.
Vejmola Č, TylšF, PioreckáV, et al.Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity. Transl Psychiatry, 2021; 11(1):506.
22.
WoodJ, KimY, MoghaddamB. Disruption of prefrontal cortex large scale neuronal activity by different classes of psychotomimetic drugs. J Neurosci, 2012; 32(9):3022–3031.
23.
CeladaP, PuigMV, Díaz-MataixL, et al. The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: Reversal by antipsychotic drugs. Biol Psychiatry, 2008; 64(5):392–400.
24.
RigaMS, SoriaG, TudelaR, et al. The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: Reversal by antipsychotic drugs. Int J Neuropsychopharmacol, 2014; 17(8):1269–1282.
25.
RigaMS, Lladó-PelfortL, ArtigasF, et al. The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT and 5-HT receptors. Neuropharmacology 2018;142:219–230.
26.
PallaviciniC, VilasMG, VillarrealM, et al. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives. Neuroimage 2019;200:281–291.
27.
Carhart-HarrisRL, MuthukumaraswamyS, RosemanL, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A, 2016; 113(17):4853–4858.
28.
MuthukumaraswamySD, LileyDT. 1/f electrophysiological spectra in resting and drug-induced states can be explained by the dynamics of multiple oscillatory relaxation processes. Neuroimage, 2018; 179:582–595.
29.
SchartnerMM, Carhart-HarrisRL, BarrettAB, et al.Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Sci Rep, 2017; 7:46421.
30.
PrellerKH, BurtJB, JiJL, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife, 2018; 7:e35082; doi: 10.7554/eLife.35082
31.
TagliazucchiE, RosemanL, KaelenM, et al. increased global functional connectivity correlates with LSD-Induced Ego Dissolution. Curr Biol, 2016; 26(8):1043–1050.
32.
MüllerF, DolderPC, SchmidtA, et al. Altered network hub connectivity after acute LSD administration. Neuroimage Clin, 2018; 18:694–701.
33.
FinkM. EEG and human psychopharmacology. Annu Rev Pharmacol, 1969; 9:241–258.
34.
FinkM. EEG and behavioral effects of psychopharmacologic agents. Neuropsychopharmacology, 1959; 1:441–446.
35.
JaimeS, GuH, SadaccaBF, et al. Delta rhythm orchestrates the neural activity underlying the resting state BOLD signal via phase-amplitude coupling. Cereb Cortex, 2019; 29(1):119–133.
36.
HermesD, NguyenM, WinawerJ.Neuronal synchrony and the relation between the blood-oxygen-level dependent response and the local field potential. PLoS Biol, 2017; 15(7):e2001461.
37.
ZhangX, PanW-J, KeilholzS.The relationship between local field potentials and the blood-oxygenation-level dependent MRI signal can be non-linear. Front Neurosci, 2019; 13:1126.
38.
Carhart-HarrisRL, LeechR, HellyerPJ, et al.The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci, 2014; 8:20.
39.
HerzogR, MedianoPAM, RosasFE, et al.A mechanistic model of the neural entropy increase elicited by psychedelic drugs. Sci Rep, 2020; 10(1):17725.
40.
SchroederCE, LakatosP. Low-frequency neuronal oscillations as instruments of sensory selection. Trends Neurosci, 2009; 32(1):9–18.
41.
Carhart-HarrisRL, ErritzoeD, WilliamsT, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A, 2012; 109(6):2138–2143.
KometerM, SchmidtA, JänckeL, et al. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci, 2013; 33(25):10544–10551.
44.
LyC, GrebAC, CameronLP, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep, 2018; 23(11):3170–3182.
45.
BeckerAM, KlaiberA, HolzeF, et al. Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Int J Neuropsychopharmacol, 2022; In Press; doi: 10.1093/ijnp/pyac075
46.
PrellerKH, HerdenerM, PokornyT, et al. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol, 2017; 27(3):451–457.
47.
BurgdorfJ, ZhangX-L, NicholsonKL, et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology, 2013; 38(5):729–742.
48.
GraefJD, NewberryK, NewtonA, et al. Effect of acute NR2B antagonist treatment on long-term potentiation in the rat hippocampus. Brain Res, 2015; 1609:31–39.
49.
YangY, JuW, ZhangH, et al.Effect of Ketamine on LTP and NMDAR EPSC in hippocampus of the chronic social defeat stress mice model of depression. Front Behav Neurosci, 2018; 12:229.
50.
BelujonP, GraceAA. Restoring mood balance in depression: Ketamine reverses deficit in dopamine-dependent synaptic plasticity. Biol Psychiatry, 2014; 76(12):927–936.
51.
AleksandrovaLR, WangYT, PhillipsAG.Ketamine and its metabolite, (2R,6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression. Mol Brain, 2020; 13(1):92.
52.
AleksandrovaLR, PhillipsAG. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci, 2021; 42(11):929–942.
53.
SaklothF, LeggettE, MoerkeMJ, et al. Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats. Exp Clin Psychopharmacol, 2019; 27(3):215–226.
54.
ElsiläLV, HarkkiJ, EnbergE, et al. Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice. J Psychopharmacol, 2022; 36(7):860–874.
55.
VaidyaVA, MarekGJ, AghajanianGK, et al. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci, 1997; 17(8):2785–2795.
56.
VollenweiderFX, PrellerKH. Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci, 2020; 21(11):611–624.
57.
BanksMI, ZahidZ, JonesNT, et al. Catalysts for change: The cellular neurobiology of psychedelics. Mol Biol Cell, 2021; 32(12):1135–1144.
58.
MartinDA, NicholsCD. The effects of hallucinogens on gene expression. Curr Top Behav Neurosci, 2018; 36:137–158.
59.
GeorgeMS. Whither TMS: A one-trick pony or the beginning of a neuroscientific revolution? Am J Psychiatry, 2019; 176(11):904–910.
60.
MironJ-P, JodoinVD, LespéranceP, et al.Repetitive transcranial magnetic stimulation for major depressive disorder: Basic principles and future directions. Ther Adv Psychopharmacol, 2021; 11:20451253211042696.
61.
MilevRV, GiacobbeP, KennedySH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical guidelines for the management of adults with major depressive disorder: Section 4. Neurostimulation treatments. Can J Psychiatry, 2016; 61(9):561–575.
62.
ColeJ, SohnMN, HarrisAD, et al. Efficacy of adjunctive D-cycloserine to intermittent theta-burst stimulation for major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 2022; 79(12):1153–1161.
63.
WackerD, WangS, McCorvyJD, et al. Crystal structure of an LSD-bound human serotonin receptor. Cell, 2017; 168(3):377–389.e12.
64.
CalderAE, HaslerG. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology, 2023; 48(1):104–112.
65.
AdayJS, DavisAK, MitzkovitzCM, et al. Predicting reactions to psychedelic drugs: A systematic review of states and traits related to acute drug effects. ACS Pharmacol Transl Sci, 2021; 4(2):424–435.
66.
VohraHZ, SaundersJM, JasterAM, et al. Sex-specific effects of psychedelics on prepulse inhibition of startle in 129S6/SvEv mice. Psychopharmacology, 2022; 239(6):1649–1664; doi: 10.1007/s00213-021-05913-9
67.
HerrKA, BakerLE. Re-evaluation of the discriminative stimulus effects of lysergic acid diethylamide with male and female Sprague-Dawley rats. Behav Pharmacol, 2020; 31(8):776–786.
68.
De GregorioD, PosaL, Ochoa-SanchezR, et al. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT, D and TAAR receptors. Pharmacol Res, 2016; 113(Pt A):81–91.
69.
CameronLP, TombariRJ, LuJ, et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature, 2021; 589(7842):474–479.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
